89 related articles for article (PubMed ID: 7229377)
1. Immunologic control of the ascites form of murine adenocarcinoma 755. IV. Characterization of the protective antibody in hyperimmune serum.
Matthews TJ; Collins JJ; Roloson GJ; Thiel HJ; Bolognesi DP
J Immunol; 1981 Jun; 126(6):2332-6. PubMed ID: 7229377
[TBL] [Abstract][Full Text] [Related]
2. Immunologic control of the ascites form of murine adenocarcinoma 755. V. Antibody-directed macrophages mediate tumor cell destruction.
Langlois AJ; Matthews T; Roloson GJ; Thiel HJ; Collins JJ; Bolognesi DP
J Immunol; 1981 Jun; 126(6):2337-41. PubMed ID: 7229378
[TBL] [Abstract][Full Text] [Related]
3. Immunologic control of a retrovirus-associated murine adenocarcinoma. VI. Augmentation of antibody-dependent killing following quantitative and qualitative changes in host peritoneal cells.
Matthews TJ; Weinhold KJ; Langlois AJ; Bolognesi DP
J Natl Cancer Inst; 1985 Oct; 75(4):703-8. PubMed ID: 3862902
[TBL] [Abstract][Full Text] [Related]
4. Immunologic control of a retrovirus-associated murine adenocarcinoma. VIII. Corynebacterium parvum-activated natural killer cells as potent antibody-dependent cell-mediated cytotoxicity effectors.
Weinhold KJ; Bolognesi DP; Matthews TJ
J Natl Cancer Inst; 1985 Oct; 75(4):717-24. PubMed ID: 3862904
[TBL] [Abstract][Full Text] [Related]
5. Immunologic control of the ascites form of murine adenocarcinoma 755. III. Efficacy of serum therapy is controlled by a single genetic locus.
Roloson GJ; Haagensen DE; Chambers CA; Bolognesi DP
J Immunol; 1981 Jun; 126(6):2328-31. PubMed ID: 7229376
[TBL] [Abstract][Full Text] [Related]
6. Immunologic control of a retrovirus-associated murine adenocarcinoma. VII. Tumor cell destruction by macrophages and IgG2A.
Langlois AJ; Matthews TJ; Weinhold KJ; Bolognesi DP
J Natl Cancer Inst; 1985 Oct; 75(4):709-15. PubMed ID: 3862903
[TBL] [Abstract][Full Text] [Related]
7. Passive transfer of antibodies protects immunocompetent and imunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication.
Gupta M; Mahanty S; Bray M; Ahmed R; Rollin PE
J Virol; 2001 May; 75(10):4649-54. PubMed ID: 11312335
[TBL] [Abstract][Full Text] [Related]
8. Antigenic modifications associated with 'spontaneous' malignant alterations of mouse fibroblasts propagated in vitro.
v F Kieler J; Oda Y; Ulrich K; Willumsen BM
Tokai J Exp Clin Med; 1983 Dec; 8(5-6):469-83. PubMed ID: 6100143
[TBL] [Abstract][Full Text] [Related]
9. The Fc portion of antibody to yellow fever virus NS1 is a determinant of protection against YF encephalitis in mice.
Schlesinger JJ; Foltzer M; Chapman S
Virology; 1993 Jan; 192(1):132-41. PubMed ID: 8517015
[TBL] [Abstract][Full Text] [Related]
10. Human IgG but not IgM antibodies can protect mice from the challenge with live O6 Escherichia coli.
Pontes GN; Massironi SG; Arslanian C; Palmeira P; Carneiro-Sampaio MM; Nagao AT
Scand J Immunol; 2005 Oct; 62(4):353-60. PubMed ID: 16253122
[TBL] [Abstract][Full Text] [Related]
11. Suppression of Ehrlich ascites tumor growth by immunization with ganglioside GT1b of its origin, its IgM antibody or anti-idiotype of the anti-GT1b IgM.
Saha S; Mondal S
Indian J Exp Biol; 2000 Dec; 38(12):1207-16. PubMed ID: 11411041
[TBL] [Abstract][Full Text] [Related]
12. Contributions of antibody and T cell subsets to protection elicited by immunization with a replication-defective mutant of herpes simplex virus type 1.
Morrison LA; Knipe DM
Virology; 1997 Dec; 239(2):315-26. PubMed ID: 9434723
[TBL] [Abstract][Full Text] [Related]
13. Induction of protective immunity in rodents by vaccination with a prokaryotically expressed recombinant fusion protein containing a respiratory syncytial virus G protein fragment.
Power UF; Plotnicky-Gilquin H; Huss T; Robert A; Trudel M; Ståhl S; Uhlén M; Nguyen TN; Binz H
Virology; 1997 Apr; 230(2):155-66. PubMed ID: 9143271
[TBL] [Abstract][Full Text] [Related]
14. Prophylactic and therapeutic efficacy of immunoglobulin G antibodies to Pseudomonas aeruginosa lipopolysaccharide against murine experimental corneal infection.
Preston MJ; Gerçeker AA; Koles NL; Pollack M; Pier GB
Invest Ophthalmol Vis Sci; 1997 Jun; 38(7):1418-25. PubMed ID: 9191605
[TBL] [Abstract][Full Text] [Related]
15. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
[TBL] [Abstract][Full Text] [Related]
16. TCR vaccines against T cell lymphoma: QS-21 and IL-12 adjuvants induce a protective CD8+ T cell response.
Wong CP; Okada CY; Levy R
J Immunol; 1999 Feb; 162(4):2251-8. PubMed ID: 9973501
[TBL] [Abstract][Full Text] [Related]
17. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
18. Poly(D,L-lactic-co-glycolic acid) microsphere delivery of adenovirus for vaccination.
Wang D; Molavi O; Lutsiak ME; Elamanchili P; Kwon GS; Samuel J
J Pharm Pharm Sci; 2007; 10(2):217-30. PubMed ID: 17706180
[TBL] [Abstract][Full Text] [Related]
19. Induction of protective host immunity to carcinoembryonic antigen (CEA), a self-antigen in CEA transgenic mice, by immunizing with a recombinant vaccinia-CEA virus.
Kass E; Schlom J; Thompson J; Guadagni F; Graziano P; Greiner JW
Cancer Res; 1999 Feb; 59(3):676-83. PubMed ID: 9973217
[TBL] [Abstract][Full Text] [Related]
20. The spontaneous release of a high-molecular-weight aggregate containing immunoglobulin G from the surface of Ehrlich ascites tumor cells.
Rittenhouse HG; Ar D; Lynn MD; Denholm DK
J Supramol Struct; 1978; 9(3):407-19. PubMed ID: 571032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
